Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453642 · ClinicalTrials.gov registry record · NA
Evaluation of a Simple-Prep Controlled Embolic
A NA study of Renal Cell Carcinoma and Bone Tumor, sponsored by Fluidx Medical Technology.
- Active
- Registry status
- NA
- Development phase
- 114
- Enrollment target
- 20
- Study locations
NCT06453642: Active NA study of Renal Cell Carcinoma and Bone Tumor, sponsored by Fluidx Medical Technology.
NCT06453642 is a NA study of Renal Cell Carcinoma and Bone Tumor that is active but no longer recruiting, run by Fluidx Medical Technology. The registered enrollment target is 114 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06453642, a NA study of Renal Cell Carcinoma and Bone Tumor, is active but no longer recruiting, sponsored by Fluidx Medical Technology.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 114 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Primary Outcome
MAEs are defined as: * Nontarget embolization with ischemia in an unintended anatomical area * Systemic allergic and/or toxic reaction to the GPX Embolic Device * Catheter entrapment and/or breakage * Culture-proven abscess in target organ/tissue * Embolization-related death
Conditions Studied
Interventions
- DEVICE GPX® Embolic Device
Study Locations (20)
New York
- Albany Medical Center - Albany
- Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Ontario
- St. Michael's Hospital - Toronto
- Toronto General Hosptial - Toronto
- Mount Sinai Hospital Toronto - Toronto
North Carolina
- University of North Carolina - Chapel Hill
- Atrium Health Carolinas Medical Center - Charlotte
Texas
- University of Texas Southwestern - Dallas
- MD Anderson Cancer Center - Interventional Radiology - Houston
Other
- Auckland City Hospital - Auckland
- Christchurch Hospital - Christchurch
California
- University of California San Diego Altman Clinical and Translation Research Institute - La Jolla
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT06453642 still lists
NCT06453642 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (53% lower).
The record links to 6 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which GPX® Embolic Device is the first listed.
NCT06453642 names 20 study sites across 13 states, led by New York, Ontario, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06453642 about?
NCT06453642 is a clinical study titled "Evaluation of a Simple-Prep Controlled Embolic". The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
What is the current status of trial NCT06453642?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 114 participants. The study started on 2024-11-18. Estimated completion is 2026-09.
What conditions does trial NCT06453642 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Bone Tumor, Embolization, Vascular Tumor, Renal Angiomyolipoma.
What interventions are being tested in trial NCT06453642?
The interventions under investigation include: GPX® Embolic Device (DEVICE).
Who is sponsoring clinical trial NCT06453642?
This trial is sponsored by Fluidx Medical Technology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06453642 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06453642's enrollment target sits among peer trials
114 49th of 121 higher than 73 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
RECRUITING · NA
-
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
RECRUITING · NA
-
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI